Dr. Bray Links

Saturday, February 11, 2017

Primary Treatment of Crohn's Disease

Given the poor activity of classic anti-tuberculous agents against Mycobacterium avium paratuberculosis (MAP), and their lack of intracellular access, where MAP is located, new antimycobacterial agents with intracellular activity against MAP, alone and in combination, were slowly introduced with improving results. Employing a combination of rifampicin, ethambutol, isoniazid and pyrazinamide or clofazimine for 9 months, Hampson et al. reported that 10 out of 20 CD patients (50%) achieved remission by 9 months.[35] Of the remaining ten, three had achieved remission by 6 months but had relapsed. Nine out of ten patients (90%) on steroids were weaned off by 9 months


No comments:

Post a Comment

Note: Only a member of this blog may post a comment.